Additionally, MK-1775 has promising synergistic antitumor effect when combined with CHK1 inhibitors LY2603618 and Sirt1 inhibitor Ex527 in various malignancies (Chen et al., 2017; Hauge et al., 2017), suggesting a novel strategy for MK-1775-mediated cancer treatment. Here, SIRT1 is linked to cancer.